2015 Press Releases

Keyword Search
 
December 21, 2015
Lion Biotechnologies Enters Clinical and Preclinical Research Collaboration With MedImmune
Research to Focus on Novel Immuno-Oncology Combination Therapies NEW YORK, Dec. 21, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has entered into a collaboration to conduct clinical and preclinical research in immuno-oncology with MedImmune, the global biologics research and development arm of AstraZeneca. Under the ter... More »
December 15, 2015
Lion Biotechnologies Announces Selection for Addition to NASDAQ Biotechnology Index
NEW YORK, Dec. 15, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has been selected for addition to the NASDAQ Biotechnology Index effective December 21, 2015. The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceut... More »
November 16, 2015
Lion Biotechnologies to Participate in Upcoming Investor Conferences
NEW YORK, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that President and CEO Elma Hawkins, PhD, will participate in the following upcoming investor conferences: Jefferies Autumn 2015 Global Healthcare Conference Date: Wednesday – Thursday, November 18-19, 2015 Location: The May Fair Hotel, London Piper Jaffray ... More »
November 9, 2015
Lion Biotechnologies Announces Agreement With WuXi AppTec to Increase TIL Manufacturing Capacity
NEW YORK, Nov. 9, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has entered into a two-year agreement with WuXi AppTec, Inc. ("WuXi AppTec") to provide additional TIL manufacturing capacity. The additional manufacturing capability is expected to become available within the first six months of 2016 at WuXi AppTec's facility... More »
November 5, 2015
Lion Biotechnologies Announces Third Quarter 2015 Financial Results
NEW YORK, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today reported financial results for the third quarter and nine months ended September 30, 2015. For the third quarter and nine months ended September 30, 2015, the Company reported operating expenses of $2.9 million and $7.5 million, respectively, compared to $2.4 million and $6.... More »
November 2, 2015
Lion Biotechnologies Announces the Departure of Dr. Laszlo Radvanyi
NEW YORK, Nov. 2, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that Dr. Laszlo Radvanyi is leaving his position of chief scientific officer of the company. "We are grateful for Laszlo's service to the company over the past year," stated Dr. Elma Hawkins, president and chief executive officer of Lion Biotechnologies. "During his ten... More »
October 7, 2015
Lion Biotechnologies Obtains Exclusive License From NIH to Develop and Commercialize TIL in Bladder, Lung, Breast and HPV-Associated Cancers
NEW YORK, Oct. 7, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has obtained an exclusive, worldwide license from the National Institutes of Health (NIH) to develop and commercialize TIL therapy in four additional tumor indications. Under the agreement, the NIH has granted Lion exclusive rights to certain patents to develop TIL ... More »
September 16, 2015
Lion Biotechnologies Announces Positive Updated Data From NCI's Phase 2 Study of TIL Therapy in the Treatment of Metastatic Melanoma
NEW YORK, Sept. 16, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that Steven A. Rosenberg, MD, PhD, chief of surgery at the National Cancer Institute (NCI), presented updated data from a Phase 2 clinical trial of TIL therapy in metastatic melanoma. The updated results were presented on September 16, 2015 at the American Associati... More »
September 14, 2015
Lion Biotechnologies Opens Enrollment in Phase 2 Study of LN-144 for the Treatment of Refractory Metastatic Melanoma
NEW YORK, Sept. 14, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO) a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has opened enrollment in a Phase 2 clinical trial of its lead product candidate, LN-144, for the treatment of refractory metastatic melanoma. The single-arm study is expected to enroll approximately 20 evaluable patients with metastatic melanoma whose dis... More »
September 3, 2015
Lion Biotechnologies to Participate in Upcoming Investor and Scientific Conferences
NEW YORK, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that president and CEO Elma Hawkins, PhD, will participate in the following upcoming investor and scientific conferences: FBR Second Annual Healthcare Conference Date: Wednesday, September 9, 2015 Location: The Four Seasons Hotel, Boston CRI-CIMT-EATI-AACR - Th... More »
August 31, 2015
Lion Biotechnologies Announces Strategic Hires
NEW YORK, Aug. 31, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced the appointments of Gregory MacMichael, PhD, as vice president of process development, and Howard B. Johnson as vice president of corporate development. Dr. MacMichael joins Lion from Novartis' Cell and Gene Therapies Therapeutic Unit, where he led process develo... More »
August 10, 2015
Lion Biotechnologies Announces Second Quarter 2015 Financial Results
NEW YORK, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today reported financial results for the second quarter and six months ended June 30, 2015. For the second quarter and six months ended June 30, 2015, the Company reported operating expenses of $2.4 million and $4.9 million, respectively, compared to $1.6 million and $3.1 million ... More »
June 24, 2015
Lion Biotechnologies to Join Russell Global Index
LOS ANGELES, June 24, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it will join the Russell Global Index on June 26, according to a list of final additions posted June 19 on the FTSE Russell website. Membership in the Russell Global Index, which remains in place for one year, means automatic inclusion in the appropriate la... More »
June 10, 2015
Lion Biotechnologies Receives Orphan Drug Designation for LN-144 for the Treatment of Malignant Melanoma
LOS ANGELES, June 10, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that the FDA has granted orphan status to the company's lead product candidate, LN-144, for the treatment of stage 2b to stage 4 malignant melanoma. The FDA grants orphan status to novel drugs or biologics to treat rare medical diseases or conditions that affe... More »
June 8, 2015
Lion Biotechnologies Names Molly Henderson Chief Financial Officer
LOS ANGELES, June 8, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced the appointment of Molly Henderson, CPA, as chief financial officer, effective immediately. Previously, Ms. Henderson served as the chief financial officer of VirtualScopics, Inc. from 2002 to 2008, and as chief business and financial officer and senior vice pr... More »
May 19, 2015
Lion Biotechnologies to Participate in Upcoming Investor Conferences
LOS ANGELES, May 19, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO) today announced that president and CEO Elma Hawkins, PhD, will participate in the following upcoming investor conferences: Piper Jaffray GenomeRx Symposium Date: Wednesday – Thursday, May 20-21, 2015 Panels: CAR-T: Engineering Lethal Lymphocytes, May 20, 10:25 am; Cellular Therapies: Toolkits and Platforms, May 20, 11:50 am Locati... More »
May 1, 2015
Lion Biotechnologies Announces Pricing of Secondary Offering of Shares by Selling Stockholders
LOS ANGELES, May 1, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes, today announced the pricing of an underwritten secondary offering of 4,750,000 shares of Lion's common stock at a price to the public of $10.00 per share. All shares were offered by the selling stockholders, including certain members of Board of Directors of the Company and certain of ... More »
April 8, 2015
Lion Biotechnologies Announces Publication of Data From Clinical Study of Metastatic Cervical Cancer Patients Treated With HPV-TIL
LOS ANGELES, April 8, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that data from a metastatic cervical cancer study conducted by the National Cancer Institute (NCI) was published in the Journal of Clinical Oncology in an article titled "Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus-T... More »
March 30, 2015
Lion Biotechnologies Announces Positive Data From a TIL-Ipilimumab Combination Study in Melanoma
LOS ANGELES, March 30, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL), today announced that researchers from Moffitt Cancer Center reported positive results from a pilot trial of TIL and ipilimumab in patients with metastatic melanoma. The data from the trial, which Lion partially sponsored, were presented at the Society of Surgical Oncology 2015 ... More »
March 3, 2015
Lion Biotechnologies Announces Closing of Underwritten Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares
LOS ANGELES, March 3, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL), today announced the closing of its underwritten public offering of 9,200,000 shares of its common stock at $8.00 per share, including 1,200,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares, resulting in gross proceeds fr... More »
March 2, 2015
Lion Biotechnologies to Present at Cowen and Company's 35th Annual Healthcare Conference
LOS ANGELES, March 2, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO) announced that president and CEO Elma Hawkins, PhD, will present at Cowen and Company's 35th Annual Healthcare Conference on Wednesday, March 4, 2015. Dr. Hawkins will present at 8:40 a.m. EST. A webcast of Dr. Hawkins' presentation will be available both live and on replay. The presentation will be available via webcast at http://wsw.com/webcast/cowen22/lbio. The live webcast and subsequent archi... More »
February 26, 2015
Lion Biotechnologies Prices Public Offering of Common Stock
LOS ANGELES, Feb. 26, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL), today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a public offering price of $8.00 per share. The gross proceeds from this offering to Lion are expected to be $64.0 million, before deducting underwriting discounts and comm... More »
February 25, 2015
Lion Biotechnologies Announces Public Offering of Common Stock
LOS ANGELES, Feb. 25, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (OTCBB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL), today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Lion expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the... More »
February 24, 2015
Lion Biotechnologies Announces Its Listing on the Nasdaq Global Market
LOS ANGELES, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has received approval to list its common stock on the Nasdaq Global Market. Lion expects its shares to begin trading on Nasdaq on Thursday, February 26, 2015 under the company's current stock symbol "LBIO". Lion's common stock is currently listed on th... More »
February 17, 2015
Lion Biotechnologies Appoints Ryan Maynard Director and Chair of Audit Committee
LOS ANGELES, Feb. 17, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that its board of directors has appointed Ryan Maynard to serve as a director and chair of the audit committee. His appointment is effective immediately. Since 2010, Mr. Maynard has served as executive vice president and chief financial officer of Rigel Pharmac... More »
February 11, 2015
Lion Biotechnologies Obtains Exclusive License From NIH for Next-Generation TIL Technology
Novel Method Enhances Quality and Efficiency of TIL Production LOS ANGELES, Feb. 11, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has obtained an exclusive, worldwide license from the National Institutes of Health (NIH) to intellectual property related for a next-generation TIL technology for the treatment of metastatic... More »
February 10, 2015
Lion Biotechnologies Obtains Exclusive License From NIH to Develop and Commercialize TIL Therapy in Metastatic Melanoma
LOS ANGELES, Feb. 10, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has obtained an exclusive, worldwide license from the National Institute of Health (NIH) to certain patents to develop and commercialize TIL therapy in the treatment of metastatic melanoma. The exclusive license was obtained through an amendment to Lion's pre... More »
February 2, 2015
Lion Biotechnologies Announces Allowance of IND Application to Begin New Phase 2 Study in Metastatic Melanoma
LOS ANGELES, Feb. 2, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that the US Food and Drug Administration (FDA) has allowed its investigational new drug (IND) application to initiate a Phase 2 study of its lead product candidate, LN-144, in the treatment of refractory metastatic melanoma. The single-arm clinical trial will be condu... More »
January 26, 2015
Lion Biotechnologies Amends CRADA With National Cancer Institute to Develop TIL Therapy for Additional Cancer Indications
LOS ANGELES, Jan. 26, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that its existing Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) has been amended to include four new tumor indications for TIL therapy. Under the modified terms of the CRADA, the NCI has granted Lion the rights to dev... More »
January 12, 2015
Lion Biotechnologies CSO Laszlo Radvanyi Co-authors Study in Clinical Cancer Research
Research Validates Method for Enhancing Quality and Efficiency of TIL Production LOS ANGELES, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL), today announced that research by chief scientific officer Laszlo Radvanyi, PhD, has been published in Clinical Cancer Research. The research, which Dr. Radvanyi conducted at MD Anderson Cancer Center with ... More »
January 5, 2015
Lion Biotechnologies Submits Investigational New Drug Application to Conduct Phase 2 Study in Metastatic Melanoma
LOS ANGELES, Jan. 5, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc., a biotechnology company that is developing novel cancer immunotherapies, today announced that it has filed an investigational new drug (IND) application with the United States Food and Drug Administration to conduct a Phase 2 clinical trial of the company's lead product candidate, LN-144, in the treatment of patients with refractory metastatic melanoma. LN-144 is a cell product of autologous tumor infiltratin... More »